title: Addition of cyclosporin-A to chemotherapy in secondary (post-MDS) AML in the elderly. A multicenter randomized trial of the Leukemia Working Group of the Hellenic Society of Hematology.
abstract: In elderly patients with secondary leukemia, poor therapeutic response and low overall survival have been attributed mainly to age and to the primary resistance of leukemic cells to chemotherapy. Modulation of resistance has been attempted in different studies, but the results have been contradictory. We conducted an open, randomized multicenter clinical trial involving patients more than 60 years old with secondary leukemia preceded by a myelodysplastic syndrome. The induction chemotherapy regimen included idarubicin, cytarabine, and etoposide (group A); randomization involved simultaneous administration of cyclosporin-A per os (group B). Fifty-five patients were evaluated, 26 in group A and 29 in group B. Overall complete remission was achieved in 40% of the patients, 27% vs 52% in groups A and B, respectively (p=0.01). Leukemia-free survival was more favorable in patients who received cyclosporin-A, 12 vs 7 months for groups B and A, respectively (p=0.03). In a follow up period of 30 months, 7 out of 55 patients (13%) were alive, 4 of whom were in complete remission. Five out of the 7 alive patients were randomized in group B and had received cyclosporin-A. Treatment failure was higher in group A [19 of 26 patients (73%)] than in group B with CsA [14 of 29 patients (48%)] (p<0.0001). Treatment-related toxicity/mortality was 13%. Modulation of drug resistance by CsA in elderly people suffering from secondary acute leukemia may improve the outcome of chemotherapy without increasing drug toxicity and treatment-related mortality.
authors.affiliation: Hematology Division, Internal Medicine Department, University Hospital Patras, Patras, Greece. matsouka@med.upatras.gr
authors.forename: P
authors.initials: P
authors.lastname: Matsouka
authors.forename: M
authors.initials: M
authors.lastname: Pagoni
authors.forename: P
authors.initials: P
authors.lastname: Zikos
authors.forename: N
authors.initials: N
authors.lastname: Giannakoulas
authors.forename: I
authors.initials: I
authors.lastname: Apostolidis
authors.forename: T
authors.initials: T
authors.lastname: Asprogeraka
authors.forename: E
authors.initials: E
authors.lastname: Arvanitopoulou
authors.forename: E
authors.initials: E
authors.lastname: Spanoudakis
authors.forename: I
authors.initials: I
authors.lastname: Kotsianidis
authors.forename: K
authors.initials: K
authors.lastname: Tsatalas
authors.forename: M
authors.initials: M
authors.lastname: Papaioannou
authors.forename: T
authors.initials: T
authors.lastname: Marinakis
authors.forename: A
authors.initials: A
authors.lastname: Skandali
authors.forename: N
authors.initials: N
authors.lastname: Viniou
authors.forename: X
authors.initials: X
authors.lastname: Yataganas
authors.forename: M
authors.initials: M
authors.lastname: Bakiri
mesh_terms: D000208:Acute Disease; D000284:Administration, Oral; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D016572:Cyclosporine / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D003561:Cytarabine / Q000008:administration & dosage / Q000627:therapeutic use; D003627:Data Interpretation, Statistical; D018572:Disease-Free Survival; D005047:Etoposide / Q000008:administration & dosage / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006115:Greece; D006801:Humans; D015255:Idarubicin / Q000008:administration & dosage / Q000627:therapeutic use; D007262:Infusions, Intravenous; D007951:Leukemia, Myeloid / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D016609:Neoplasms, Second Primary / Q000188:drug therapy*; D012074:Remission Induction; D012955:Societies, Medical; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D003561:Cytarabine; D005047:Etoposide; D016572:Cyclosporine; D015255:Idarubicin